Development and Validation of HPLC Method for Diphenhydramine Hydrochloride

Hina Javed*, Syed Nisar Hussain Shah, Nida Javed
Faculty of pharmacy, Department. of Pharmaceuticals, Bahauddin Zakariya University, Multan, Pakistan.

ABSTRACT

Aim: The aim of present method development for Diphenhydramine HCl performed on HPLC is to obtain specific, more accurate and precise results as compare to spectrophotometric method.

Methods: HPLC analysis was performed according to USP method with wavelength detection at 220nm and 1.0ml/min flow rate. Wufeng thermo HPLC system UV -100detector was used having column C18(4.6mm*250mm)
5. Methanol and water (4:1) mixture was used as mobile phase and pH was adjusted at 7.4 with the help of triethanolamine. Validation parameters like linearity, accuracy, precision, solution stability, robustness, LOD, LOQ and system suitability were successfully evaluated.

Results: The regression co-efficient for calibration curve was 0.991 and % recovery was in range (80-110%), whereas no robustness was observed in this reported method.

Conclusion: In summary, the expected linearity, accuracy and % recovery indicating that HPLC is more precise method than spectrophotometry and suggested that present method qualifies the validation criteria.

Keywords: Diphenhydramine HCl, HPLC, Method Validation, LOD, LOQ, Robustness.

INTRODUCTION

High performance liquid chromatography (HPLC) is one of the analytical method used for validation of drugs and chemical substances [1, 2]. Diphenhydramine HCl (Figure 1) is antihistaminic drug substance, widely used in the treatment of allergic rhinitis, common cold and skin allergies. DPH is H1 receptor antagonist, white crystalline powder having melting point 168-172°C. Diphenhydramine HCl is lipophilic in nature and well absorbed from nasal cavity. Its molecular weight is 291.82 g/mol (less than 1KDa), rapidly absorbed transcellularly across the nasal membrane. It can cross Blood Brain Barrier (BBB) having 40-60% bioavailability and metabolize in liver [3-5].

*Address of Correspondence Author: j_hain2003@yahoo.com

Figure 1. The chemical structure of Diphenhydramine HCl.
parameters are the important indicators of system functionality, sample preparation and column [6, 7].

**EXPERIMENTAL**

**Chemicals**
Diphenhydramine hydrochloride was gifted from Pfizer pharmaceuticals, Karachi (Pakistan). Methanol of HPLC analytical grade was purchased from Merck, Germany. Double distilled water was used gifted from Zakfas Pharmaceuticals Multan (Pakistan).

**Instrumentation**
HPLC system (Wufeng thermo UV 100 detector, China), Lamp, Ultrasonic bath (shenzhen co., China), Plungers and Plunger seals (7725i, USA), Syringe and Syringe filters, Needle assembly, vials, pH meter (PHS-3E, China), Magnetic stirrer (stuart,UC 152)

**Chromatographic Condition**
Column: C18 (4.6 mm * 250 mm) 5
Mobile phase: methanol: water: Triethanolamine (40:10:0.5), adjust pH at 7.4
Diluent: methanol: water (40:10)
Flow rate: 1.2mL/min
Column temperature: 25°C
UV detection: 220 nm
Injection volume: 10µL
Membrane disc filters (0.45µm pore size)

**Preparation of Mobile Phase**
Mobile phase was prepared by mixing the 40ml methanol (HPLC-analytical grade) with 10 ml double distilled water (4:1, V/V) and pH was adjusted at 7.4 with the help of Triethanolamine (0.5ml). Then filtered the mobile phase through 0.45µm pore size filter paper under vacuum and degassed through ultrasonic bath before use.

**Preparation of Standard Solution**
Stock solution (100 µg/mL) of DPH was prepared in diluent (4:1; methanol; water) in volumetric flask. Standard solutions were prepared by making further dilutions by adding mobile phase over concentration range 10, 20, 30, 40 and 50 µg/mL, to 20,40,60,80 and 100% in mobile phase respectively.

**Chromatographic Method for Validation**
According to the ICH-Guidelines, parameters for chromatographic validation were determined such as linearity, precision, LOD, LOQ, solution stability and system suitability [8].

**Linearity**
It describes the relationship between response and analyte concentration over the range. For the evaluation, linearity range depends on purpose of analytical method [9]. ICH guideline specify the minimum, five concentration levels with minimum specified range. The linearity data is accepted by observing the values of Regression coefficient ($r^2$≤1), y-intercept (less than percent response obtained for analyte), slope and % relative standard deviation (% RS) [10]. In present study, linearity for DPH was determined over the concentration range of 10-50µg/mL (n=3).

**Specificity of Assay**
In order to detect any interference between reference standard solution of DPH, placebo and mobile phase, specificity was evaluated by comparing chromatograms of 3 replicate injections of reference standard solution and placebo [11].

**Accuracy**
Accuracy is the closeness of test values to the true values of method [11]. In this study, it was obtained by preparing the sample solution over range of 10-50µg/mL (n=3) and % recovery was calculated. According to USP for acceptance of accuracy criteria, the %recovery must be in range 80-110%.

**Precision**
Intra-day assay measures the degree of repeatability of analytical method under normal specific conditions. The intra-batch precision is determined under same condition over short interval of time. In present study, it was determined by selecting the three different concentrations (20,30 and 40 µg/mL, n=3) at three different consecutive days.

The mean, standard deviation and % RSD were calculated for both intra-day and inter-day precision.
**Limit of Detection (LOD) and Limit of Quantitation (LOQ)**

Limit of Detection (LOD) is the lowest amount of analyte, detected at three times the noise level \((S/N=3)\) [6] and calculated by:

\[
LOD = 3.3 \times SD/m
\]

Whereas SD is the standard deviation and \(m\) is the slope of calibration curve.

While LOQ is the lowest amount of analyte that reproducible quantified above baseline noise \((S/N=10)\) [6] and calculated by:

\[
LOQ = 10 \times SD/m
\]

Whereas SD is the standard deviation and \(m\) is the slope of calibration curve.

In present study, 20µL injection of DPH (10 µg/mL, \(n=3\)) standard used to calculating the LOD and LOQ with % RSD.

**Analytical Solutions Stability**

It was measured by keeping the mobile phase and standard solutions in capped volumetric flask in laboratory for 48 hours under normal conditions and was assessed at 12 hours intervals and determined the %RSD of DPH standard solutions [13].

**Robustness**

It was determined by observing the changes in various experimental conditions. Three standard solutions were prepared and then analyzed by using established conditions and by make variation in some chromatographic conditions. The changes in mobile phase pH (±0.3) and composition (±3), wavelength (±1 nm) and experimental temperature (±2°C) were made and obtained the data that was then subjected for statistical analysis by using analysis of variance (ANOVA) test.

**System Suitability Test**

It is the most important step in HPLC analysis, used for the verification of accuracy and precision of system [14]. In present study, system suitability was performed on HPLC system by injecting 10 injections of same concentration of DPH (10 µg/mL), assessed with mobile phase. The different parameters such as theoritical plates per column, tailing factor, %RSD of peak area and %RSD of retention time were calculated.

**RESULTS AND DISCUSSION**

**Linearity**

The calibration curve of Diphenhydramine HCl was linear over the concentration range of 10-50 µg/mL. Three injections of each concentration were applied and regression equation \((Y=180063X+222402)\) was obtained by plotting the injecting concentration (µg/mL) against obtained peak area \((Y)\). The value of correlation coefficient \((r^2=0.991)\) has shown the significantly good relationship between injecting concentration (µg/mL) and obtained peak area \((Y)\) as shown in Figure 2. The data for linearity was obtained for this experiment has been tabulated in Table 1 that showed %RSD was less than 1 for each concentration of standard solutions. This linearity data is in agreement with spectrophotometrically analytical method as previously reported in literature [15].

| Injected concentration | Retention time (min) | DPH height (µv) | DPH Peak area (µvs) | DPH mean Peak area SD | DPH mean Peak area %RSD |
|------------------------|----------------------|-----------------|---------------------|-----------------------|------------------------|
| 10 µg/mL               | 14.17                | 22740           | 1710462             | 0.816497              | 4.77×10⁻⁵              |
| 20 µg/mL               | 14.19                | 53553           | 4049980             | 0.816497              | 2.02×10⁻⁵              |
| 30 µg/mL               | 14.29                | 84725           | 5830335.5           | 1.247219              | 2.14×10⁻⁵              |
| 40 µg/mL               | 14.28                | 108995          | 7584088.5           | 0.816497              | 1.08×10⁻⁵              |
| 50 µg/mL               | 14.40                | 132298          | 8946539.1           | 0.77603               | 8.67×10⁻⁶              |
Specificity of Assay
The specificity of this method was analyzed for reference standard solution of DPH, Placebo and mobile phase by applying separate injections of each. There was no interfering peak was observed as in Figure 3.

Accuracy
The accuracy was determined by repeating three injections of each concentration (10, 20, 30, 40 and 50 µg/mL) of DPH in mobile phase at 220nm. The mean % recovery for each concentration was calculated as described in Table 2 that was in range (80-110%) according to USP with %RSD less than 1.

Table 2. Accuracy of DPH-HCl from Standard Solutions of Known Concentrations (n=3).

| Injected concentration | Obtained concentration | % Recovery | % RSD |
|------------------------|------------------------|------------|-------|
| 10 µg/mL               | 8.264 µg/mL            | 82.64      | 0.988 |
| 20 µg/mL               | 21.256 µg/mL           | 106.28     | 0.768 |
| 30 µg/mL               | 31.144 µg/mL           | 103.814    | 0.786 |
| 40 µg/mL               | 40.883 µg/mL           | 102.21     | 0.798 |
| 50 µg/mL               | 48.45 µg/mL            | 96.90      | 0.842 |
Precision

Repeatability (Intra-Day Assay)

The intra-day precision was evaluated by injecting the 10 injections of 10 µg/mL concentration at same experimental conditions. Mean % RSD for Retention time, peak Height, peak area and obtained concentration was less than 1 as tabulated in Table 3.

Intermediate Precision (Inter-Day Assay)

Inter-day precision was evaluated by injecting the three injections of selected three concentrations (20, 30 and 40 µg/mL) on different consecutive days. The retention time, peak area, obtained concentration and % recovery was observed and data showed mean % RSD for % recovery was less than 1 as tabulated in Table 4.

Table 3. Repeatability of HPLC Assay for DPH-HCl by Replicate Injections (n=10) for Concentration (10µg/mL).

| Injection number | Retention time (min) | Peak height (µv) | Peak area (µv s) | Obtained conc. (µg/mL) |
|------------------|----------------------|-----------------|-----------------|------------------------|
| 1                | 14.17                | 22740           | 1710462         | 8.2641                 |
| 2                | 14.16                | 22736           | 1710455         | 8.264                  |
| 3                | 14.165               | 22738           | 171459          | 8.264                  |
| 4                | 14.17                | 22740           | 1710462         | 8.2641                 |
| 5                | 14.165               | 22738           | 1710459         | 8.264                  |
| 6                | 14.15                | 22733           | 1710448         | 8.264                  |
| 7                | 14.167               | 22739           | 1710457         | 8.264                  |
| 8                | 14.157               | 22736           | 1710443         | 8.264                  |
| 9                | 14.162               | 22737           | 1710459         | 8.264                  |
| 10               | 14.168               | 22739           | 1710461         | 8.264                  |
| mean             | 14.1634              | 22737.6         | 1710457         | 8.26402                |
| SD               | 0.006                | 2.059           | 5.97            | 4*10^-5                |
| % RSD            | 0.042                | 0.009           | 0.0003          | 4.84*10^-6             |

Table 4. Demonstration of Intermediate Precision of HPLC Assay for DPH-HCl Reported Method.

| Injected concentration (µg/mL) (n=3) | RT (min) | Peak area (µv s) (n=3) | Obtained conc. (µg/mL) (n=3) | % Recovery | % RSD |
|-------------------------------------|----------|------------------------|-----------------------------|------------|-------|
| 20                                  | 14.19    | 4049980                | 21.256                      | 106.28     | 0.768 |
| 30                                  | 14.29    | 5830335.5              | 31.144                      | 103.814    | 0.786 |
| 40                                  | 14.28    | 7584088.5              | 40.883                      | 102.21     | 0.798 |

Figure 4. HPLC Chromatogram of DPH solution for (A) LOD & (B) LOQ.
LOD and LOQ
Limit of Detection and Limit of Quantitation by injecting the known lowest concentration (10µg/mL) at three and ten times S/N response for DPH was 1.49×10^-5 µg/mL and 4.5×10^-5 µg/mL respectively. The graph of LOD and LOQ has shown in Figure 4 (A&B).

Analytical Solution Stability
The stability of Diphenhydramine hydrochloride and mobile phase was calculated by comparing area percent and area response two standards at 10µg/ml over specific time for 48 hours. The standard solution has shown no significant change in DPH concentration throughout this time period as described in Table 5. This was indicated by RSD less than 1% changes in peak area, obtained concentration and recovery between T=0 hours and T=48 hours. This data also showed no significant quantitative change in % recovery and as well retention time within 48 hours.

Robustness
Changes observed for pH (±0.3) and composition of mobile phase (±3 %), wavelength determination (±1 nm) and experimental temperature (±2°C), produced no affect in present developed method. This indicates developed analytical method has high level of robustness as no significant differences were observed by changing the chromatographic conditions.

System Suitability Test
In present study, this test was performed to determine the accuracy and precision of HPLC system by injecting 10 injections of 10 µg/mL DPH. The results showed that mean % RSD for peak area and retention time was less than 1(0.0003 and 0.042 respectively). While the tailing factor was less than 2 (1.06) and theoretical plates were greater than 2000 (7076.7) as shown in Table 6.

Table 5. Stability of DPH-HCl in Solution (n=3).

| Time (hours) | Retention time (min) | Peak Area (µv) RSD (%) | Obtained conc. (µg/mL) RSD (%) | Recovery (%) RSD (%) |
|--------------|---------------------|------------------------|-------------------------------|----------------------|
| 0            | 14.17               | 4.77 *10^-5            | 0.009                         | 0.988                |
| 24           | 14.21               | 4.79 *10^-5            | 0.012                         | 0.991                |
| 48           | 14.24               | 4.83 *10^-5            | 0.015                         | 0.995                |

Table 6. System Suitability of HPLC Assay for DPH-HCl (n=10).

| System Suitability Parameters | Acceptance Criteria | Results |
|-------------------------------|---------------------|---------|
| Injection precision for Peak area | RSD ≤ 1% | 0.0003  |
| Injection precision for RT(min) | RSD ≤ 1% | 0.042   |
| Tailing factor (T) for DPH-HCl peak | T ≤ 2 | 1.06    |
| Theoretical plates (N) for DPH-HCl peak | N = > 2000 | 7076.7   |

CONCLUSION
HPLC analysis of drug substances and validation is complexed and time consuming method. But in spite of all these, it is more precise and accurate analytical technique. This article is intended in providing the guidance to perform validation method for HPLC that generates useful data in order to meet all requirements of USP, ICH and FDA for the validation of DPH analysis.

REFERENCES
1. Guideline IH. Text on validation of analytical procedures. InInternational Conference on Harmonization, Geneva 1994 Oct (pp. 1-5).
2. Guideline IHT. Validation of analytical procedures: text and methodology. Q2 (R1). 2005;1(20):05.
3. Hardman JG, Limbird LE. Goodman and Gilman’s the pharmacological basis of therapeutics. New York. 2001;2000:953-7.
4. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and
Development and Validation of HPLC Method for Diphenhydramine Hydrochloride

therapeutic aspects. International journal of pharmaceutics. 2007;337(1):1-24.

5. Kim DD. In vitro cellular models for nasal drug absorption studies. InDrug Absorption Studies 2008 (pp. 216-234). Springer, Boston, MA.

6. Shabir GA. A practical approach to validation of HPLC methods under current good manufacturing practices. Journal of validation technology. 2004;10(3):210-8.

7. Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. Journal of chromatography A. 2003;987(1):57-66.

8. Kumar V, Bhutani H, Singh S. ICH guidance in practice: validated stability-indicating HPLC method for simultaneous determination of ampicillin and cloxacillin in combination drug products. Journal of pharmaceutical and biomedical analysis. 2007;43(2):769-73.

9. Suntornsuk L. Capillary electrophoresis in pharmaceutical analysis: A survey on recent applications. Journal of chromatographic science. 2007;45(9):559-19.

10. Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Journal of pharmacology & pharmacotherapeutics. 2015;6(3):185.

11. Naveed S. Analytical Determination of Lisinopril Using UV Spectrophotometer and HPLC: An Overview. Modern Chemistry & Applications. 2014; 2(137):2.

12. Tzanavaras PD, Themelis DG. Review of recent applications of flow injection spectrophotometry to pharmaceutical analysis. Analytica Chimica Acta. 2007;588(1):1-9.

13. Thanikachalam S, Rajappan M, Kannappan V. Stability-indicating HPLC method for simultaneous determination of pantoprazole and domperidone from their combination drug product. Chromatographia. 2008;67(1-2):41-7.

14. Basavaiah K, Prameela H. Simple spectrophotometric determination of acyclovir in bulk drug and formulations. Il Farmaco. 2002;57(6):443-9.

15. Syed Askary Ul Hassan.; Method Development of Diphenhydramine HCl (C17H21NO.HCl) On Spectrophotometer. IOSR Journal of Applied Chemistry 2015;8(3): 59-62.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.